Work

Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series

Year: 2024

Type: article

Source: Vaccine

DOI: 10.1016/j.vaccine.2024.05.081

Authors: Amy C. Sherman, Simon D. van Haren, Ella Borberg, Zoe Swank, Muneerah Aleissa, Alexandra Tong, Rebecca Rooks, Urwah Kanwal, Hannah Levine, Bridget Yates, Natalie Izaguirre, Kevin Ryff, Sanya Thomas, Lindsey Parisi, Xiaofang Li, David R. Walt, Ofer Levy, Stephen R. Walsh, Nicolas C. Issa, Lindsey R. Baden

Institutions: Brigham and Women's Hospital, Boston Children's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Wyss Institute for Biologically Inspired Engineering, Princess Nourah bint Abdulrahman University, Emory University, Broad Institute

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Institutes of Health, National Center for Advancing Translational Sciences

Award: The Harvard Clinical and Translational Science Center

OpenAlex ID: W4399559418

FWCI: 2.205

Cites: 12

Cited by: 7

Related to: 10